Please ensure Javascript is enabled for purposes of website accessibility

Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA

By Cory Renauer – Updated Feb 13, 2020 at 1:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Patients with HER2-positive breast cancer could have a new treatment option from Seattle Genetics this summer.

On Thursday, Seattle Genetics (SGEN) shared some good news regarding an experimental breast cancer drug called tucatinib. The U.S. Food and Drug Administration (FDA) will give tucatinib's new drug application a priority review.

From 10 months to six

Patients with HER2-positive breast cancer tumors that keep growing after treatment multiple rounds of standard care could have another treatment option this summer. 

Dice with letters that spell out FDA.

Image source: Getty Images

Instead of the standard 10-month process, the FDA granted tucatinib a priority review that will shave four months off the timeline. The agency's expected to announce a decision on or before Aug. 20, 2020. 

A slam dunk 

The priority review the FDA gives tucatinib will most likely result in a positive approval decision on or before the FDA's action date. During the HER2Climb study that's supporting Seattle Genetics' new drug application, adding tucatinib to a standard regimen of chemotherapy plus Herceptin reduced patients' risk of death significantly. Two years after beginning treatment, 44.9% of patients given tucatinib plus standard care were still alive compared to a 26.6% survival rate for patients given standard care alone.

Roughly half of all patients with HER2-positive breast cancer develop brain tumors that are incredibly difficult to treat. Seattle Genetics' potential new cancer therapy appears to give this underserved population a fighting chance for long-term survival. During the HER2Climb trial, none of the patients with brain metastases given standard care survived past one year without signs of their disease worsening compared to an impressive 24.9% of those treated with the tucatinib-containing regimen.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
SGEN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.